These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 18528223)

  • 1. Transient marked elevation of serum CA 19-9 levels in a patient with acute cholangitis and biliary stent.
    Chintanaboina J; Badari AR; Gopavaram D; Qazi KJ
    South Med J; 2008 Jun; 101(6):661. PubMed ID: 18528223
    [No Abstract]   [Full Text] [Related]  

  • 2. Biliary obstruction induces extremely elevated serum CA 19-9 levels: case report.
    Onal C; Colakoglu T; Ulusan SN; Yapar AF; Kayaselcuk F
    Onkologie; 2012; 35(12):780-2. PubMed ID: 23207625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An elderly man with a postcholecystectomy bile leak.
    Ponchon T; Baillie J
    Endoscopy; 2000 Jul; 32(7):585-8. PubMed ID: 10917191
    [No Abstract]   [Full Text] [Related]  

  • 4. Markedly elevated serum CA 19-9 levels in association with a benign biliary stricture due to primary sclerosing cholangitis.
    Murray MD; Burton FR; Di Bisceglie AM
    J Clin Gastroenterol; 2007 Jan; 41(1):115-7. PubMed ID: 17198074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extremely elevated CA19-9 in acute cholangitis.
    Sheen-Chen SM; Sun CK; Liu YW; Eng HL; Ko SF; Kuo CH
    Dig Dis Sci; 2007 Nov; 52(11):3140-2. PubMed ID: 17404889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient with markedly elevated CA 19-9 not associated with malignancy.
    Lowe D; Lee J; Schade R; Chaudhary A
    South Med J; 2006 Mar; 99(3):306-8. PubMed ID: 16553110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endoscopic/laparoscopic versus open surgical management of choledocholithiasis.
    Yarze JC; Herlihy KJ
    Dig Dis Sci; 2008 May; 53(5):1432. PubMed ID: 18231854
    [No Abstract]   [Full Text] [Related]  

  • 8. Autoimmune cholangitis and cholangiocarcinoma.
    Li J; Zhao C; Shen Y
    J Gastroenterol Hepatol; 2012 Dec; 27(12):1783-9. PubMed ID: 23034143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three late adverse events of choledochoduodenostomy of which the endoscopist should be aware: direct retrograde cholangioscopy is helpful for diagnosis and therapy.
    Albert JG; Tal A; Bechstein WO; Trojan J; Schnitzbauer A
    Gastrointest Endosc; 2015 Feb; 81(2):463-4. PubMed ID: 25028272
    [No Abstract]   [Full Text] [Related]  

  • 10. False elevation of CA 19-9 levels in a patient with a history of pancreatic cancer.
    Goetz M; Steen PD
    Am J Gastroenterol; 1997 Aug; 92(8):1390-1. PubMed ID: 9260821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve.
    Kim HJ; Kim MH; Myung SJ; Lim BC; Park ET; Yoo KS; Seo DW; Lee SK; Min YI
    Am J Gastroenterol; 1999 Jul; 94(7):1941-6. PubMed ID: 10406263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atypical courses of serum tumor markers--4 case reports.
    Klapdor R; Bahlo M; Babinski A
    Anticancer Res; 2003; 23(2A):845-50. PubMed ID: 12820311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simple cholangitis induces extremely and recurrently elevated serum carbohydrate antigen 19-9 level.
    Xu DL; Wu YQ; Xin C; Zhou QF; Chen ML; Yan HJ
    Hepatobiliary Pancreat Dis Int; 2019 Jun; 18(3):294-295. PubMed ID: 30981634
    [No Abstract]   [Full Text] [Related]  

  • 14. Measurement of serum CA 19-9 in biliary diseases requires great caution.
    Dorizzi RM; Di Leo A; Guglielmi A; de Manzoni G
    Acta Oncol; 2001; 40(7):877-8. PubMed ID: 11859990
    [No Abstract]   [Full Text] [Related]  

  • 15. Persistent elevation of serum CA 19-9 with no evidence of malignant disease.
    Ventrucci M; Pozzato P; Cipolla A; Uomo G
    Dig Liver Dis; 2009 May; 41(5):357-63. PubMed ID: 18602352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative serum CA 19-9 level as a predictive factor for recurrence after curative resection in biliary tract cancer.
    Chung MJ; Lee KJ; Bang S; Park SW; Kim KS; Lee WJ; Song SY; Chung JB; Park JY
    Ann Surg Oncol; 2011 Jun; 18(6):1651-6. PubMed ID: 21210227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complex postcholecystectomy biliary disorders: preliminary experience with evaluation by means of breath-hold MR cholangiography.
    Coakley FV; Schwartz LH; Blumgart LH; Fong Y; Jarnagin WR; Panicek DM
    Radiology; 1998 Oct; 209(1):141-6. PubMed ID: 9769825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors.
    Engelen MJ; de Bruijn HW; Hollema H; ten Hoor KA; Willemse PH; Aalders JG; van der Zee AG
    Gynecol Oncol; 2000 Jul; 78(1):16-20. PubMed ID: 10873403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extraordinarily elevated CA19-9 in benign conditions: a case report and review of the literature.
    Akdoğan M; Saşmaz N; Kayhan B; Biyikoğlu I; Dişibeyaz S; Sahin B
    Tumori; 2001; 87(5):337-9. PubMed ID: 11765186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Increased CA-19-9 caused by a splenic cyst: a rare differential diagnosis].
    Decker D; Bollmann R; Hirner A; Stratmann H
    Zentralbl Chir; 1998; 123(7):855-7. PubMed ID: 9746988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.